Abstract:Abstract Gliomas are the most common primary brain tumors. Glioblastoma multiforme (GBM), WHO grade IV, is the most frequent and aggressive form, with a median survival of approximately 12 months following aggressive treatment with surgical resection, radiation and chemotherapy. Epidermal growth factor receptor (EGFR) is frequently amplified and mutated in human cancers including GBM. While the rationale for treating GBM patients with EGR inhibitors is strong, the efficacy of anti-EGFR small molecular inhibitors or monoclonal antibodies in treating gliomas with PTEN mutation or deletion has been modest. Here we show a novel approach to inhibiting EGFR that involves a small molecule (G5-7) that selectively blocks JAK2 phosphorylation of EGFR, inhibits cell proliferation and reduces VEGF secretion, and leads to glioma shrinkage via apoptosis and anti-angiogenesis. G5-7 inhibited EGFR and STAT3 tyrosine phosphorylation by JAK2 through binding to its N-terminal FERM domain. Interestingly, G5-7 selectively inhibited the proliferation of U87MG/EGFRvIII cells and human GBM explant neurosphere cultures but only weakly affected U87MG/PTEN cells or normal neural progenitor cultures. Moreover, oral administration of this compound markedly diminishes the brain tumor volumes in both subcutaneous and intracranial models, supporting that this compound itself and/or the metabolites might be able to penetrate the brain-blood barrier and exert the anti-proliferative actions through blocking the oncogenic pathways in vivo. Chronic treatment of mice with 50 mg/kg G5-7 exhibits no obvious toxicity in the animals. Our finding demonstrates that G5-7 is a novel allosteric JAK2 inhibitor with potent anti-tumor activity for GBM. Our report not onlyidentify a novel drug for treating the GBM, but also provide insight into the molecular mechanisms of how these small molecules impinge on the EGFR/PTEN signaling. Optimization of these novel compounds will lead to new treatments for the patients with these devastating tumors. [K.H. and Q.Q. contributed equally to this work.] Citation Format: Kunyan He, Qi Qi, Chi-Bun Chan, Ge Xiao, Xia Liu, Carol Tucker-Burden, Liya Wang, Hui Mao, Xiang Lu, Frank E. McDonald, Hongbo Luo, Qi-wen Fan, William A. Weiss, Shi-yong Sun, Daniel J. Brat, Keqiang Ye. Blockade of glioma proliferation via allosteric inhibition of JAK2. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5683. doi:10.1158/1538-7445.AM2013-5683

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

LDHB Promotes the Growth of Glioma Cells via PDK1/Akt/GSK3p Pathway

Phosphoglycerate Kinase 1 Gene Knockdown Suppresses The Migration And Invasion Of Glioma Cells

Identification of a Novel Non-Atp-competitive Protein Kinase Inhibitor of PGK1 from Marine Nature Products.

Phosphoglycerate Kinase 1 Promotes Radioresistance in U251 Human Glioma Cells.

Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models

Phosphatase and Tensin Homolog Reconstruction and Vascular Endothelial Growth Factor Knockdown Synergistically Inhibit the Growth of Glioblastoma

Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo

Phosphoglycerate Dehydrogenase Induces Glioma Cells Proliferation and Invasion by Stabilizing Forkhead Box M1.

Blockade Of Glioma Proliferation Via Allosteric Inhibition Of Jak2

The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells

Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma

The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1

Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro

Abstract LB136: Characterization of a novel PI3Kinase inhibitor for treatment of glioblastoma multiforme

Gambogenic acid-induced time- and dose-dependent growth inhibition and apoptosis involving Akt pathway inactivation in U251 glioblastoma cells

The Neurogenic Compound P7C3 Regulates the Aerobic Glycolysis by Targeting Phosphoglycerate Kinase 1 in Glioma

Blockade of glioma proliferation through allosteric inhibition of JAK2.

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

The Oncogenic Role and Regulatory Mechanism of PGK1 in Human Non-Small Cell Lung Cancer

DDEL-08. NOVEL COMBINATION THERAPY USING PI3KINASE INHIBITION AND IMMUNE BASED THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME